Kaitlin Kestenberg-Messina Sells 10,096 Shares of ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) COO Kaitlin Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded up $0.02 during mid-day trading on Tuesday, reaching $15.83. The company had a trading volume of 2,159,176 shares, compared to its average volume of 3,409,757. The company has a 50-day moving average price of $16.81 and a two-hundred day moving average price of $16.74. ADMA Biologics Inc has a 1-year low of $13.76 and a 1-year high of $25.67. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The stock has a market cap of $3.77 billion, a PE ratio of 26.38 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.20. The company had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.46 EPS. On average, equities analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus target price of $32.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in ADMA Biologics during the 3rd quarter worth about $25,000. Rothschild Investment LLC boosted its stake in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,495 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $29,000. Clearstead Advisors LLC grew its position in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the third quarter worth approximately $34,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.